NWK Group’s Neurocrine Biosciences NBIX Stock Holding History

NWK Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-590	Closed	-$57K	–	195
2020 Q4	$57K	Buy	+590	New	+$57K	0.02%	103

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

NWK Group's NBIX Position: Q1 2021 in Review

NWK Group sold out of Neurocrine Biosciences (NBIX) in Q1 2021, closing a stake of 590 shares — an estimated $57K sold.

NWK Group first reported a position in NBIX in Q4 2020 and held it in 1 quarter. The position peaked at $57K in Q4 2020. 419 funds tracked by Wall St. Rank hold NBIX as of Q1 2021.

NWK Group reported no remaining Neurocrine Biosciences position as of Q1 2021 after selling out during the quarter.
NWK Group sold 590 Neurocrine Biosciences shares in Q1 2021, an estimated $57K.
NWK Group first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 1 quarter.
NWK Group's Neurocrine Biosciences position peaked at $57K in Q4 2020.
419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2021.

Based on NWK Group's 13F filing for Q1 2021, filed 14 May 2021.